Collegium Pharmaceutical (NASDAQ:COLL) highlighted a “record-breaking” 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results